Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study

Published on January 21, 2022

Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

Continue reading on website
Other news

Key Factors to Impact Boston Properties (BXP) in Q4 Earnings

January 21, 2022
With the recovery in the job market as well as high demand for life-science assets, Boston Properties' (BXP) portfolio performance is likely to have improved in Q4.

Webster (WBS) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

January 21, 2022
Webster Financial's (WBS) Q4 earnings results reflect higher revenues and improved organic growth despite a low-rate economy that hurts margins.